[Nonpuerperal mastitis]. 1985

C Pohl, and K Decker, and A E Schindler

The medical history of 37 women with nonpuerperal mastitis, who had been treated between January 1980 and July 1983 at the Dept. of Obstetrics and Gynaecology of the University of Tübingen, was reviewed because of the increasing prevalence of this disease. Defined by different history and clinical symptoms, two groups of patients were seen: 25 women with acute nonpuerperal mastitis and 12 women with chronic recurring nonpuerperal mastitis. The average age of the patients was 30 years. The inflammation was located mostly subareolar and around the nipple. The main symptoms were pain, erythema and swelling, in acute cases accompanied by fever and abscess formation. This process was strongly related to the interval between the onset of symptoms and the initiation of treatment. Anaerobes and Staphylococcus aureus could be cultured mainly from women with acute nonpuerperal mastitis. In females with chronic recurrent mastitis, mostly anaerobes were found. Women were treated with a prolactin inhibitor (bromocriptine), if abscess formation, leukocytosis or fever were absent. In patients with leukocytosis and/or fever this regimen was combined with antibiotics. Abscesses were treated surgically, in some cases in combination with prolactin inhibition and antibiotic administration. The results show that an early conservative treatment is important to prevent abscess formation. It seems that this treatment can reduce the rate of recurrences.

UI MeSH Term Description Entries
D008413 Mastitis INFLAMMATION of the BREAST, or MAMMARY GLAND.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005348 Fibrocystic Breast Disease A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency. Breast Dysplasia,Fibrocystic Mastopathy,Mammary Dysplasia,Adenosis of Breast,Chronic Cystic Mastitis,Cystic Breast Disease,Cystic Disease of Breast,Fibrocystic Changes of Breast,Fibrocystic Disease of Breast,Microglandular Adenosis,Adenoses, Microglandular,Adenosis, Microglandular,Breast Adenosis,Breast Cystic Disease,Breast Cystic Diseases,Breast Disease, Cystic,Breast Disease, Fibrocystic,Breast Fibrocystic Change,Breast Fibrocystic Changes,Breast Fibrocystic Disease,Cystic Mastitis, Chronic,Disease, Cystic Breast,Disease, Fibrocystic Breast,Dysplasia, Breast,Dysplasia, Mammary,Mastopathy, Fibrocystic,Microglandular Adenoses

Related Publications

C Pohl, and K Decker, and A E Schindler
February 2006, The Journal of pediatrics,
C Pohl, and K Decker, and A E Schindler
March 1983, Obstetrics and gynecology,
C Pohl, and K Decker, and A E Schindler
March 1989, JAMA,
C Pohl, and K Decker, and A E Schindler
February 1985, Der Radiologe,
C Pohl, and K Decker, and A E Schindler
January 1989, Fortschritte der Medizin,
C Pohl, and K Decker, and A E Schindler
February 2014, AJR. American journal of roentgenology,
C Pohl, and K Decker, and A E Schindler
October 2002, European journal of obstetrics, gynecology, and reproductive biology,
C Pohl, and K Decker, and A E Schindler
January 1985, Geburtshilfe und Frauenheilkunde,
C Pohl, and K Decker, and A E Schindler
June 2011, Journal of magnetic resonance imaging : JMRI,
C Pohl, and K Decker, and A E Schindler
September 1978, Geburtshilfe und Frauenheilkunde,
Copied contents to your clipboard!